FDA issues warning letters to drugmakers in China, India and the US over GMP violations

The U.S. Food and Drug Administration has issued warning letters to a number of manufacturers in China, India and the United States.

The letters cite multiple violations of good manufacturing practices in the production of active pharmaceutical ingredients and finished drug products.

The firms must correct the problems promptly to avoid further regulatory action.